112 related articles for article (PubMed ID: 8467286)
21. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
22. rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial.
Legros M; Fleury J; Bay JO; Choufi B; Basile M; Condat P; Glenat C; Communal Y; Tavernier F; Bons JM; Chollet P; Plagne R; Chassagne J
Bone Marrow Transplant; 1997 Feb; 19(3):209-13. PubMed ID: 9028547
[TBL] [Abstract][Full Text] [Related]
23. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
[TBL] [Abstract][Full Text] [Related]
24. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
25. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
26. The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous bone marrow transplantation.
Nemunaitis JJ; Singer JW; Sanders JE
Bone Marrow Transplant; 1991; 7 Suppl 3():24-7. PubMed ID: 1855082
[TBL] [Abstract][Full Text] [Related]
27. Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant.
Vela-Ojeda J; Tripp-Villanueva F; Sanchez-Cortés E; Ayala-Sanchez M; García-Ruiz Esparza MA; Rosas-Cabral A; Gonzalez-Llaven J
Bone Marrow Transplant; 1999 Dec; 24(12):1307-10. PubMed ID: 10627639
[TBL] [Abstract][Full Text] [Related]
28. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies.
Richard C; Alsar MJ; Calavia J; Bello-Fernandez C; Baro J; Loyola I; Rios R; Cuadrado MA; Gonzalez-Pardo C; Iriondo A
Bone Marrow Transplant; 1993 Jun; 11(6):473-8. PubMed ID: 8334429
[TBL] [Abstract][Full Text] [Related]
32. Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter study.
Fay JW; Lazarus H; Herzig R; Saez R; Stevens DA; Collins RH; Piñeiro LA; Cooper BW; DiCesare J; Campion M
Blood; 1994 Oct; 84(7):2151-7. PubMed ID: 7919329
[TBL] [Abstract][Full Text] [Related]
33. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial.
Luce BR; Singer JW; Weschler JM; Buckner CD; Sheingold SH; Shannon-Dorcy K; Appelbaum FR; Nemunaitis J
Pharmacoeconomics; 1994 Jul; 6(1):42-8. PubMed ID: 10172083
[TBL] [Abstract][Full Text] [Related]
34. No increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantation.
Gupta P; Tiley C; Powles R; Treleaven J; Millar J; Catalano J
Bone Marrow Transplant; 1992 Jun; 9(6):491-3. PubMed ID: 1628135
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with rhGM-CSF and rhEpo for two patients with refractory anemia and aplastic anemia.
Takahashi M; Aoki A; Mito M; Nikkuni K; Ohtsuka T; Saitoh H; Moriyama Y; Shibata A
Hematol Pathol; 1993; 7(3):153-8. PubMed ID: 8244908
[TBL] [Abstract][Full Text] [Related]
36. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
38. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
[TBL] [Abstract][Full Text] [Related]
39. Effect of antimicrobial prophylaxis on hematopoietic recovery following autologous bone marrow transplantation: ciprofloxacin versus co-trimoxazole.
Imrie KR; Prince HM; Couture F; Brandwein JM; Keating A
Bone Marrow Transplant; 1995 Feb; 15(2):267-70. PubMed ID: 7773216
[TBL] [Abstract][Full Text] [Related]
40. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study.
Valcárcel D; Sanz MA; Sureda A; Sala M; Muñoz L; Subirá M; Laborda R; Clopés A; Sierra J
Bone Marrow Transplant; 2002 May; 29(9):783-7. PubMed ID: 12040477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
